Airain Ltd’s Coherus Oncology CHRS Stock Holding History

Airain Ltd’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-13,371	Closed	-$376K	–	824
2016 Q4	$376K	Buy	+13,371	New	+$374K	0.03%	444

Other funds holding CHRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Airain Ltd's CHRS Position: Q1 2017 in Review

Airain Ltd sold out of Coherus Oncology (CHRS) in Q1 2017, closing a stake of 13,371 shares — an estimated $376K sold.

Airain Ltd first reported a position in CHRS in Q4 2016 and held it in 1 quarter. The position peaked at $376K in Q4 2016. 109 funds tracked by Wall St. Rank hold CHRS as of Q1 2017.

Airain Ltd reported no remaining Coherus Oncology position as of Q1 2017 after selling out during the quarter.
Airain Ltd sold 13,371 Coherus Oncology shares in Q1 2017, an estimated $376K.
Airain Ltd first reported a position in Coherus Oncology in Q4 2016 and held it in 1 quarter.
Airain Ltd's Coherus Oncology position peaked at $376K in Q4 2016.
109 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2017.

Based on Airain Ltd's 13F filing for Q1 2017, filed 9 May 2017.